Evaluation of adverse events of tremelimumab, a recently FDA-approved anti-CTLA-4 antibody for non-small cell lung cancer - Milan 2023

The 3 Ts of lung cancer management: targets, treatment response and troubles

Chair(s): Georgia Hardavella, Wouter H. van Geffen

Session type: Poster session

Evaluation of adverse events of tremelimumab, a recently FDA-approved anti-CTLA-4 antibody for non-small cell lung cancer

Jing Huang

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Study of the efficacy of intravenous BCG in a metastatic lung adenocarcinoma mouse model.

Claudia Guerrero

Poster

Abstract

Circulating tumor cells in patients with lung cancer universally indicate poor prognosis

Fukang Jin

Poster

Abstract

Comparing the Effectiveness of Different Anti-angiogenetic Agents Combined with an EGFR-TKI in Metastatic Lung Adenocarcinoma

Chung-wen Huang

Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection

Kristina Krpina

Abstract

Evaluation of adverse events of tremelimumab, a recently FDA-approved anti-CTLA-4 antibody for non-small cell lung cancer

Jing Huang

Poster

Abstract

Extracellular vesicles derived from central nervous system suppresses antitumor immunity

Jiaoli Wang

Abstract

CD8+ T cell trajectory subtypes determine clinical outcome and therapy response in LUAD

Benteng Deng

Poster

Abstract

Possible Risk Factors for Immune Related Pneumonitis Relapses

Lidia Mendez Mangas

Poster

Abstract

Exploration of anticancer drug response prediction model using patient derived organoids with ALK-positive lung cancer

Hyeong Jun Cho

Poster

Abstract

PD-L1 expression on NSCLC lung tumors is affected by the presence of COPD.

Martina Maria Ferrara

Poster

Abstract

Prognostic implication of KRAS G12C mutation in a real-world KRAS mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands

Anneloes L. Noordhof

Poster

Abstract

Relationship between age and chemotherapy regimen for elderly patients with advanced lung cancer

Abstract

Exploiting the kynurenine pathway to combat platinum-resistant non-small cell lung cancer (NSCLC)

Medhi Wangpaichitr

Poster

Abstract

Clinical risk factors for checkpoint pneumonitis vs. other pneumonitis in lung cancer patients treated with checkpoint inhibitors

Lukas Wehlte

Abstract

Identification of predictive factors for early relapse in patients with unresectable stage ? NSCLC receiving consolidation durvalumab after concurrent chemoradiation therapy

Jung Hyun Nam

Poster

Abstract

Quantitative analysis of preoperative, intraoperative and postoperative circulating cell-free DNA in patients with resectable non-small cell lung cancer

Stylianos Gaitanakis

Poster

Abstract

Biomarkers in non-small cell lung cancer patients: are they always worth looking for?

Michele Barp

Poster

Abstract

The long-term outcome of epidermal growth factor receptor mutation in stage IV lung adenocarcinoma patients.

Chung-jen Huang

Poster

Abstract

Smoking status at time of diagnosis affects the efficacy of anti-PD-1/L1 therapy in patients with advanced non-small cell lung cancer

Kim Kyu Yean

Poster

Abstract

Late Breaking Abstract - Probe-based Confocal Laser Endomicroscopy (pCLE) As A Tool In Lung Cancer Diagnosis In Ecuador

Efrain Sanchez Angarita

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}